Patient and donor/recipient characteristics
| Median patient age, y (range) | 37 (5-71) |
| Age groups, n (%) | |
| < 20 y | 13 (16) |
| 20-50 y | 44 (55) |
| > 50 y | 23 (29) |
| Patient sex, n (%) | |
| Male | 52 (65) |
| Female | 28 (35) |
| Malignant diseases | |
| Standard-risk, n (disease status) | 45 |
| AML | 34 (CR1 = 21; CR2 = 13) |
| ALL | 10 (CR1 = 8; CR2 = 2) |
| Plasma cell leukemia | 1 (CR1 = 1) |
| High-risk, n (disease status) | 35 |
| AML | 11 (CR3 = 2; AD = 9) |
| ALL | 5 (CR3 = 1; AD = 4) |
| Hodgkin lymphoma | 5 (AD = 5) |
| CML | 5 (CP2 = 4; AD = 1) |
| Myelodysplastic syndrome | 3 (AD = 3) |
| Non-Hodgkin lymphoma | 2 (AD = 2) |
| Myelofibrosis | 2 (AD = 2) |
| Plasma cell leukemia | 2 (AD = 2) |
| Median donor age, y (range) | 39 (16-72) |
| Patient sex, n (%) | |
| Male | 43 (54) |
| Female | 37 (46) |
| Donor/recipient relationship, n (%) | |
| Sibling | 38 (47) |
| Mother | 20 (25) |
| Children | 17 (22) |
| Father | 4 (5) |
| Cousin | 1 (1) |
| Donor/recipient sex, n (%) | |
| Male/male | 28 (35) |
| Female/male | 24 (30) |
| Male/female | 15 (19) |
| Female/female | 13 (16) |
| Donor/recipient CMV serostatus, n (%) | |
| Positive/positive | 55 (69) |
| Negative/positive | 14 (17) |
| Positive/negative | 8 (10) |
| Negative/negative | 3 (4) |
| ABO match, n (%) | |
| Minor mismatched | 12 (15) |
| Major mismatched | 30 (38) |
| Matched | 38 (47) |
| No. of HLA-A, HLA-B, HLA-DRB1 antigens mismatched | |
| 2 | 28 (35) |
| 3 | 52 (65) |
| Median patient age, y (range) | 37 (5-71) |
| Age groups, n (%) | |
| < 20 y | 13 (16) |
| 20-50 y | 44 (55) |
| > 50 y | 23 (29) |
| Patient sex, n (%) | |
| Male | 52 (65) |
| Female | 28 (35) |
| Malignant diseases | |
| Standard-risk, n (disease status) | 45 |
| AML | 34 (CR1 = 21; CR2 = 13) |
| ALL | 10 (CR1 = 8; CR2 = 2) |
| Plasma cell leukemia | 1 (CR1 = 1) |
| High-risk, n (disease status) | 35 |
| AML | 11 (CR3 = 2; AD = 9) |
| ALL | 5 (CR3 = 1; AD = 4) |
| Hodgkin lymphoma | 5 (AD = 5) |
| CML | 5 (CP2 = 4; AD = 1) |
| Myelodysplastic syndrome | 3 (AD = 3) |
| Non-Hodgkin lymphoma | 2 (AD = 2) |
| Myelofibrosis | 2 (AD = 2) |
| Plasma cell leukemia | 2 (AD = 2) |
| Median donor age, y (range) | 39 (16-72) |
| Patient sex, n (%) | |
| Male | 43 (54) |
| Female | 37 (46) |
| Donor/recipient relationship, n (%) | |
| Sibling | 38 (47) |
| Mother | 20 (25) |
| Children | 17 (22) |
| Father | 4 (5) |
| Cousin | 1 (1) |
| Donor/recipient sex, n (%) | |
| Male/male | 28 (35) |
| Female/male | 24 (30) |
| Male/female | 15 (19) |
| Female/female | 13 (16) |
| Donor/recipient CMV serostatus, n (%) | |
| Positive/positive | 55 (69) |
| Negative/positive | 14 (17) |
| Positive/negative | 8 (10) |
| Negative/negative | 3 (4) |
| ABO match, n (%) | |
| Minor mismatched | 12 (15) |
| Major mismatched | 30 (38) |
| Matched | 38 (47) |
| No. of HLA-A, HLA-B, HLA-DRB1 antigens mismatched | |
| 2 | 28 (35) |
| 3 | 52 (65) |
AD indicates active disease; and CP, chronic phase.